BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 38521213)

  • 1. Bruton's Tyrosine Kinase Deficiency Inhibits Autoimmune Arthritis in Mice but Fails to Block Immune Complex-Mediated Inflammatory Arthritis.
    Nyhoff LE; Barron BL; Johnson EM; Bonami RH; Maseda D; Fensterheim BA; Han W; Blackwell TS; Crofford LJ; Kendall PL
    Arthritis Rheumatol; 2016 Aug; 68(8):1856-68. PubMed ID: 26945549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
    Park JK; Byun JY; Park JA; Kim YY; Lee YJ; Oh JI; Jang SY; Kim YH; Song YW; Son J; Suh KH; Lee YM; Lee EB
    Arthritis Res Ther; 2016 Apr; 18():91. PubMed ID: 27090981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of Novel Bruton's Tyrosine Kinase PROTACs with Enhanced Selectivity and Cellular Efficacy.
    Li YQ; Lannigan WG; Davoodi S; Daryaee F; Corrionero A; Alfonso P; Rodriguez-Santamaria JA; Wang N; Haley JD; Tonge PJ
    J Med Chem; 2023 Jun; 66(11):7454-7474. PubMed ID: 37195170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Bruton's Tyrosine Kinase (BTK) Substrates for Time-Resolved Luminescence Assays.
    Widstrom NE; Perez M; Pratt ED; Heier JL; Blankenhorn JF; Breidenbach L; Peterson H; Parker LL
    ACS Chem Biol; 2022 Jun; 17(6):1328-1333. PubMed ID: 35653784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery and Preclinical Characterization of BIIB129, a Covalent, Selective, and Brain-Penetrant BTK Inhibitor for the Treatment of Multiple Sclerosis.
    Himmelbauer MK; Bajrami B; Basile R; Capacci A; Chen T; Choi CK; Gilfillan R; Gonzalez-Lopez de Turiso F; Gu C; Hoemberger M; Johnson DS; Jones JH; Kadakia E; Kirkland M; Lin EY; Liu Y; Ma B; Magee T; Mantena S; Marx IE; Metrick CM; Mingueneau M; Murugan P; Muste CA; Nadella P; Nevalainen M; Parker Harp CR; Pattaropong V; Pietrasiewicz A; Prince RJ; Purgett TJ; Santoro JC; Schulz J; Sciabola S; Tang H; Vandeveer HG; Wang T; Yousaf Z; Helal CJ; Hopkins BT
    J Med Chem; 2024 May; 67(10):8122-8140. PubMed ID: 38712838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Navigating a paradigm shift: Bruton's tyrosine kinase inhibitors redefining the landscape of multiple sclerosis therapy.
    Rao AG
    Int Immunopharmacol; 2024 Jun; 135():112265. PubMed ID: 38781611
    [No Abstract]   [Full Text] [Related]  

  • 7. BTK drives neutrophil activation for sterilizing antifungal immunity.
    Desai JV; Zarakas MA; Wishart AL; Roschewski M; Aufiero MA; Donkó Á; Wigerblad G; Shlezinger N; Plate M; James MR; Lim JK; Uzel G; Bergerson JR; Fuss I; Cramer RA; Franco LM; Clark ES; Khan WN; Yamanaka D; Chamilos G; El-Benna J; Kaplan MJ; Staudt LM; Leto TL; Holland SM; Wilson WH; Hohl TM; Lionakis MS
    J Clin Invest; 2024 May; 134(12):. PubMed ID: 38696257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bruton tyrosine kinase inhibitors in multiple sclerosis: evidence and expectations.
    Krämer J; Wiendl H
    Curr Opin Neurol; 2024 Jun; 37(3):237-244. PubMed ID: 38533819
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Structure-Activity Investigation of the Fungal Metabolite (-)-TAN-2483B: Inhibition of Bruton's Tyrosine Kinase.
    McCone JAJ; Teesdale-Spittle PH; Flanagan JU; Harvey JE
    Chemistry; 2024 Jun; 30(35):e202401051. PubMed ID: 38629656
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel Tyrosine Kinase 2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.
    Sabnis RW
    ACS Med Chem Lett; 2024 Jun; 15(6):769-770. PubMed ID: 38894908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: Mapping genetic vulnerabilities reveals BTK as a novel therapeutic target in oesophageal cancer.
    Gut; 2024 Jun; ():. PubMed ID: 38866472
    [No Abstract]   [Full Text] [Related]  

  • 12. Bruton's Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials.
    Rozkiewicz D; Hermanowicz JM; Kwiatkowska I; Krupa A; Pawlak D
    Molecules; 2023 Mar; 28(5):. PubMed ID: 36903645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bruton's Tyrosine Kinase (BTK) Inhibitors and Autoimmune Diseases: Making Sense of BTK Inhibitor Specificity Profiles and Recent Clinical Trial Successes and Failures.
    Ringheim GE; Wampole M; Oberoi K
    Front Immunol; 2021; 12():662223. PubMed ID: 34803999
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.
    Neys SFH; Rip J; Hendriks RW; Corneth OBJ
    Drugs; 2021 Sep; 81(14):1605-1626. PubMed ID: 34609725
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bruton's Tyrosine Kinase Inhibitors: The Next Frontier of B-Cell-Targeted Therapies for Cancer, Autoimmune Disorders, and Multiple Sclerosis.
    Garg N; Padron EJ; Rammohan KW; Goodman CF
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of Bruton's tyrosine kinase as emerging therapeutic strategy in autoimmune diseases.
    De Bondt M; Renders J; Struyf S; Hellings N
    Autoimmun Rev; 2024 May; 23(5):103532. PubMed ID: 38521213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A review of Bruton's tyrosine kinase inhibitors in multiple sclerosis.
    Airas L; Bermel RA; Chitnis T; Hartung HP; Nakahara J; Stuve O; Williams MJ; Kieseier BC; Wiendl H
    Ther Adv Neurol Disord; 2024; 17():17562864241233041. PubMed ID: 38638671
    [TBL] [Abstract][Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.